Do analysts recommend PALI or RLYB?

Palisade Bio presently has a consensus target price of $9.00, indicating a potential upside of 374.93%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.00 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, PALI or RLYB?

Rallybio has higher revenue and earnings than Palisade Bio. Rallybio is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Palisade Bio $250K 1,315.74 -$16.78M -$1.01 N/A Rallybio $860K 98.17 -$8.98M -$4.34 N/A

Is PALI or RLYB more profitable?

Palisade Bio has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Palisade Bio's return on equity of -36.79% beat Rallybio's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -36.79% -34.34% Rallybio -911.07% -55.79% -51.48%

Does the media refer more to PALI or RLYB?

In the previous week, Palisade Bio had 1 more articles in the media than Rallybio. MarketBeat recorded 3 mentions for Palisade Bio and 2 mentions for Rallybio. Palisade Bio's average media sentiment score of 0.95 beat Rallybio's score of 0.95 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate LXEO or RLYB?

Lexeo Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 354.00%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Lexeo Therapeutics is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to LXEO or RLYB?

In the previous week, Lexeo Therapeutics had 2 more articles in the media than Rallybio. MarketBeat recorded 4 mentions for Lexeo Therapeutics and 2 mentions for Rallybio. Lexeo Therapeutics' average media sentiment score of 1.39 beat Rallybio's score of 0.95 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RLYB or AKBA?

Akebia Therapeutics has a consensus target price of $4.67, indicating a potential upside of 253.54%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akebia Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Does the media prefer RLYB or AKBA?

In the previous week, Akebia Therapeutics had 1 more articles in the media than Rallybio. MarketBeat recorded 3 mentions for Akebia Therapeutics and 2 mentions for Rallybio. Rallybio's average media sentiment score of 0.95 beat Akebia Therapeutics' score of 0.00 indicating that Rallybio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer RLYB or RCKT?

Rocket Pharmaceuticals has a consensus target price of $8.71, indicating a potential upside of 180.20%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rocket Pharmaceuticals 3 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.30

Does the media refer more to RLYB or RCKT?

In the previous week, Rocket Pharmaceuticals had 5 more articles in the media than Rallybio. MarketBeat recorded 7 mentions for Rocket Pharmaceuticals and 2 mentions for Rallybio. Rallybio's average media sentiment score of 0.95 beat Rocket Pharmaceuticals' score of 0.38 indicating that Rallybio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ORGO or RLYB?

Organogenesis currently has a consensus target price of $5.75, suggesting a potential upside of 142.62%. Given Organogenesis' stronger consensus rating and higher probable upside, analysts plainly believe Organogenesis is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, ORGO or RLYB?

Organogenesis has higher revenue and earnings than Rallybio. Organogenesis is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organogenesis $564.17M 0.54 $37.03M -$0.19 N/A Rallybio $860K 98.17 -$8.98M -$4.34 N/A

Is ORGO or RLYB more profitable?

Organogenesis has a net margin of -0.84% compared to Rallybio's net margin of -911.07%. Organogenesis' return on equity of 9.63% beat Rallybio's return on equity. Company Net Margins Return on Equity Return on Assets Organogenesis -0.84% 9.63% 4.76% Rallybio -911.07% -55.79% -51.48%

Does the media favor ORGO or RLYB?

In the previous week, Organogenesis had 1 more articles in the media than Rallybio. MarketBeat recorded 3 mentions for Organogenesis and 2 mentions for Rallybio. Rallybio's average media sentiment score of 0.95 beat Organogenesis' score of 0.67 indicating that Rallybio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rallybio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rallybio (RLYB) Competitors

$15.93 -0.14 (-0.87%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$15.94 +0.02 (+0.09%)

As of 07/31/2026 04:10 PM Eastern

Compare

RLYB vs. PALI, LXEO, AKBA, RCKT, and ORGO

Should you buy Rallybio stock or one of its competitors? MarketBeat compares Rallybio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rallybio include Palisade Bio (PALI), Lexeo Therapeutics (LXEO), Akebia Therapeutics (AKBA), Rocket Pharmaceuticals (RCKT), and Organogenesis (ORGO).

How does Rallybio compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

In the previous week, Palisade Bio had 1 more articles in the media than Rallybio. MarketBeat recorded 3 mentions for Palisade Bio and 2 mentions for Rallybio. Palisade Bio's average media sentiment score of 0.95 beat Rallybio's score of 0.95 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market.

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 10.3% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Rallybio has higher revenue and earnings than Palisade Bio. Rallybio is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,315.74	-$16.78M	-$1.01	N/A
Rallybio	$860K	98.17	-$8.98M	-$4.34	N/A

Palisade Bio presently has a consensus target price of $9.00, indicating a potential upside of 374.93%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Palisade Bio has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Palisade Bio's return on equity of -36.79% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
Rallybio	-911.07%	-55.79%	-51.48%

Summary

Palisade Bio beats Rallybio on 13 of the 17 factors compared between the two stocks.

How does Rallybio compare to Lexeo Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Lexeo Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market.

Lexeo Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 354.00%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Lexeo Therapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Rallybio has higher revenue and earnings than Lexeo Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Rallybio	$860K	98.17	-$8.98M	-$4.34	N/A

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 10.3% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lexeo Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Lexeo Therapeutics' return on equity of -47.48% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Rallybio	-911.07%	-55.79%	-51.48%

In the previous week, Lexeo Therapeutics had 2 more articles in the media than Rallybio. MarketBeat recorded 4 mentions for Lexeo Therapeutics and 2 mentions for Rallybio. Lexeo Therapeutics' average media sentiment score of 1.39 beat Rallybio's score of 0.95 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lexeo Therapeutics beats Rallybio on 12 of the 16 factors compared between the two stocks.

How does Rallybio compare to Akebia Therapeutics?

Rallybio (NASDAQ:RLYB) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Akebia Therapeutics has higher revenue and earnings than Rallybio. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	98.17	-$8.98M	-$4.34	N/A
Akebia Therapeutics	$236.20M	1.50	-$5.34M	-$0.08	N/A

Rallybio has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Akebia Therapeutics has a consensus target price of $4.67, indicating a potential upside of 253.54%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akebia Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

90.3% of Rallybio shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 10.3% of Rallybio shares are held by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Akebia Therapeutics has a net margin of -8.83% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-55.79%	-51.48%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

In the previous week, Akebia Therapeutics had 1 more articles in the media than Rallybio. MarketBeat recorded 3 mentions for Akebia Therapeutics and 2 mentions for Rallybio. Rallybio's average media sentiment score of 0.95 beat Akebia Therapeutics' score of 0.00 indicating that Rallybio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Akebia Therapeutics beats Rallybio on 10 of the 16 factors compared between the two stocks.

How does Rallybio compare to Rocket Pharmaceuticals?

Rallybio (NASDAQ:RLYB) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Rallybio has a beta of -0.9, indicating that its share price is 190% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-55.79%	-51.48%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

In the previous week, Rocket Pharmaceuticals had 5 more articles in the media than Rallybio. MarketBeat recorded 7 mentions for Rocket Pharmaceuticals and 2 mentions for Rallybio. Rallybio's average media sentiment score of 0.95 beat Rocket Pharmaceuticals' score of 0.38 indicating that Rallybio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rocket Pharmaceuticals has a consensus target price of $8.71, indicating a potential upside of 180.20%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Rallybio has higher revenue and earnings than Rocket Pharmaceuticals. Rallybio is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	98.17	-$8.98M	-$4.34	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 10.3% of Rallybio shares are owned by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Rocket Pharmaceuticals beats Rallybio on 11 of the 16 factors compared between the two stocks.

How does Rallybio compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 18.8% of Organogenesis shares are held by insiders. Comparatively, 10.3% of Rallybio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Organogenesis has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Rallybio has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market.

In the previous week, Organogenesis had 1 more articles in the media than Rallybio. MarketBeat recorded 3 mentions for Organogenesis and 2 mentions for Rallybio. Rallybio's average media sentiment score of 0.95 beat Organogenesis' score of 0.67 indicating that Rallybio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rallybio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organogenesis has a net margin of -0.84% compared to Rallybio's net margin of -911.07%. Organogenesis' return on equity of 9.63% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Rallybio	-911.07%	-55.79%	-51.48%

Organogenesis has higher revenue and earnings than Rallybio. Organogenesis is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.54	$37.03M	-$0.19	N/A
Rallybio	$860K	98.17	-$8.98M	-$4.34	N/A

Organogenesis currently has a consensus target price of $5.75, suggesting a potential upside of 142.62%. Given Organogenesis' stronger consensus rating and higher probable upside, analysts plainly believe Organogenesis is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Organogenesis beats Rallybio on 12 of the 16 factors compared between the two stocks.

Get Rallybio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLYB vs. The Competition

Export

Metric	Rallybio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$84.40M	$3.55B	$7.16B	$12.47B
Dividend Yield	N/A	3.78%	2.59%	9.45%
P/E Ratio	-3.67	7.38	282.25	24.66
Price / Sales	98.17	1,254.29	583.24	88.79
Price / Cash	N/A	98.58	71.23	59.99
Price / Book	1.45	16.80	11.09	5.90
Net Income	-$8.98M	-$12.46M	$3.50B	$336.31M
7 Day Performance	-2.33%	-1.47%	-0.24%	0.09%
1 Month Performance	0.76%	-8.45%	-3.70%	-5.17%
1 Year Performance	272.20%	48.32%	61.98%	18.61%

Rallybio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLYB Rallybio	1.6574 of 5 stars	$15.93 -0.9%	N/A	+272.2%	$84.40M	$860K	N/A	40	News Coverage Upcoming Earnings
PALI Palisade Bio	2.9063 of 5 stars	$1.95 -3.7%	$9.00 +362.7%	+87.6%	$337.61M	$250K	N/A	10
LXEO Lexeo Therapeutics	2.2725 of 5 stars	$4.26 -3.0%	$18.75 +340.1%	-10.4%	$334.50M	N/A	N/A	58	News Coverage Positive News Analyst Upgrade
AKBA Akebia Therapeutics	1.9353 of 5 stars	$1.25 -2.0%	$4.67 +274.8%	-64.5%	$333.98M	$236.20M	N/A	430	Upcoming Earnings
RCKT Rocket Pharmaceuticals	2.8972 of 5 stars	$3.05 -3.0%	$8.71 +186.2%	+4.0%	$333.58M	N/A	N/A	240	News Coverage Upcoming Earnings Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLYB) was last updated on 8/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rallybio (RLYB) Competitors

RLYB vs. PALI, LXEO, AKBA, RCKT, and ORGO

How does Rallybio compare to Palisade Bio?

Summary

How does Rallybio compare to Lexeo Therapeutics?

Summary

How does Rallybio compare to Akebia Therapeutics?

Summary

How does Rallybio compare to Rocket Pharmaceuticals?

Summary

How does Rallybio compare to Organogenesis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB vs. The Competition

Rallybio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rallybio (RLYB) Competitors

RLYB vs. PALI, LXEO, AKBA, RCKT, and ORGO

How does Rallybio compare to Palisade Bio?

Does the media refer more to PALI or RLYB?

Which has more volatility & risk, PALI or RLYB?

Do institutionals & insiders have more ownership in PALI or RLYB?

Which has higher valuation and earnings, PALI or RLYB?

Do analysts recommend PALI or RLYB?

Is PALI or RLYB more profitable?

Summary

How does Rallybio compare to Lexeo Therapeutics?

Which has more volatility & risk, LXEO or RLYB?

Do analysts rate LXEO or RLYB?

Which has preferable valuation and earnings, LXEO or RLYB?

Do insiders and institutionals believe in LXEO or RLYB?

Is LXEO or RLYB more profitable?

Does the media refer more to LXEO or RLYB?

Summary

How does Rallybio compare to Akebia Therapeutics?

Which has preferable valuation & earnings, RLYB or AKBA?

Which has more volatility and risk, RLYB or AKBA?

Do analysts prefer RLYB or AKBA?

Do institutionals & insiders have more ownership in RLYB or AKBA?

Is RLYB or AKBA more profitable?

Does the media prefer RLYB or AKBA?

Summary

How does Rallybio compare to Rocket Pharmaceuticals?

Which has more risk and volatility, RLYB or RCKT?

Is RLYB or RCKT more profitable?

Does the media refer more to RLYB or RCKT?

Do analysts prefer RLYB or RCKT?

Which has stronger earnings and valuation, RLYB or RCKT?

Do insiders and institutionals believe in RLYB or RCKT?

Summary

How does Rallybio compare to Organogenesis?

Do insiders and institutionals believe in ORGO or RLYB?

Which has more risk and volatility, ORGO or RLYB?

Does the media favor ORGO or RLYB?

Is ORGO or RLYB more profitable?

Which has stronger earnings & valuation, ORGO or RLYB?

Do analysts prefer ORGO or RLYB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLYB vs. The Competition

Rallybio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools